Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its vitiligo program will feature in presentations to be given at this week’s American Academy of Dermatology (AAD) 73rd Annual Meeting in San Francisco. Data from Clinuvel’s vitiligo program will be reviewed and discussed by experts involved in the CUV102 and CUV103 clinical trials, where SCENESSE® has been used as a combination repigmentation treatment for darker skinned vitiligo patients.
“We are seeing an increasing recognition of the need to treat vitiligo in practical dermatology, which is reflected in the number of presentations featuring Clinuvel’s program,” Clinuvel’s Director, Clinical Affairs, Dr Emilie Rodenburger said. “There are few public forums like the AAD which truly allow our thinking and data on the treatment of vitiligo to be presented to, and challenged by, a global audience of leading academics and practitioners. Given we’re the first pharmaceutical company to fully focus on the treatment of vitiligo, this feedback remains invaluable to our program.”
The AAD meeting is the largest of its type anywhere in the world, with nearly 20,000 attendees from across the globe, and will run from March 20-24
Presentations – American Academy of Dermatology 73rd Annual Meeting, The Moscone Center San Francisco
Grimes, P. What’s New in Vitiligo Therapy? March 21, 4:05pm, Room 3022.
Hamzavi, I. Newer Systemic Treatments for Vitiligo. March 24, 11am, Room 2014.
Hamzavi, I. Combinated therapies. March 24, 1.30pm, Room 120.
Hamzavi, I. Overview and Vitiligo. March 24, 3.30pm, Room 120.
Henderson, M. Vitiligo: What’s New? March 20, 11.30am, Room 2014.
Lim, H. News on afamelanotide. March 24, 2pm, Room 120.
- End -
Lachlan Hay, Clinuvel Pharmaceuticals Ltd. +61 3 96604900
Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540
Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been granted marketing authorisation under exceptional circumstance by the European Medicines Agency for adults with EPP. Based in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore.
For more information go to http://www.clinuvel.com.
Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide 16mg) for a range of UV-related and pigmentary skin disorders. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:
actual results may and often will differ materially from these forward-looking statements;
no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place.
Level 14 / 190 Queen Street T +61 3 9660 4900 www.clinuvel.com
Melbourne, Victoria 3000F +61 3 9660 4999